Jazz Net Interest Income from 2010 to 2024

JAZZ Stock  USD 124.34  2.33  1.84%   
Jazz Pharmaceuticals Net Interest Income yearly trend continues to be fairly stable with very little volatility. Net Interest Income is likely to outpace its year average in 2024. Net Interest Income is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. View All Fundamentals
 
Net Interest Income  
First Reported
2019-03-31
Previous Quarter
-62 M
Current Value
-58.7 M
Quarterly Volatility
26.4 M
 
Covid
Check Jazz Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jazz Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 303.9 M, Other Operating Expenses of 3.4 B or Operating Income of 607.5 M, as well as many indicators such as Price To Sales Ratio of 1.93, Dividend Yield of 0.0 or PTB Ratio of 2.98. Jazz financial statements analysis is a perfect complement when working with Jazz Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Jazz Pharmaceuticals Correlation against competitors.

Latest Jazz Pharmaceuticals' Net Interest Income Growth Pattern

Below is the plot of the Net Interest Income of Jazz Pharmaceuticals PLC over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Jazz Pharmaceuticals' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jazz Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Interest Income10 Years Trend
Slightly volatile
   Net Interest Income   
       Timeline  

Jazz Net Interest Income Regression Statistics

Arithmetic Mean(126,614,470)
Coefficient Of Variation(78.39)
Mean Deviation84,315,489
Median(72,261,000)
Standard Deviation99,256,963
Sample Variance9851.9T
Range231.3M
R-Value(0.81)
Mean Square Error3597.8T
R-Squared0.66
Significance0.0002
Slope(18,043,176)
Total Sum of Squares137927.2T

Jazz Net Interest Income History

2024-278.6 M
2023-293.2 M
2022-288.2 M
2021-278.8 M
2020-99.7 M
2019-72.3 M
2018-77.1 M

About Jazz Pharmaceuticals Financial Statements

Jazz Pharmaceuticals investors use historical fundamental indicators, such as Jazz Pharmaceuticals' Net Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jazz Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Interest Income-293.2 M-278.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.